European regulators have agreed to undertake an accelerated assessment of Eisai’s lenvatinib as a treatment for progressive radioiodine-refractory, differentiated thyroid cancer. The drug, which carries Orphan Status in the EU, is to be filed “imminently” and could become the … Continue reading
August 3, 2014
by PharmaReviews
0 comments